The stock’s 2016 performance made it one of the best-performing biotech stocks of the year. That’s great news for investors who jumped aboard the fast-moving Exelixis train early.
Category: Kidney Cancer
The 3 Biggest Risks for Pfizer in 2017
Could the new year present better opportunities for the big pharma? Yes, but challenges remain. Here are three of Pfizer’s biggest risks in 2017.